Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of V72P10: 18-Month Antibody Persistence After Vaccination
2014-004992-21Phase 3
- Sponsor
- Novartis
- Start
- Nov 2014
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Primary immunogenicity endpoints.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-004992-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004992-21.